UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40690 Identification No.) (I.R.S.Employer (State or other jurisdiction of incorporationororganization) RxSIGHT, INC. (Exact N ...

Exhibit 99.1 RXSIGHT, INC. REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Aliso Viejo, Calif. (NASDAQ: RXST) – November 7, 2024 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2024. Key Quarterly Highlights • Reported third quarter 2024 revenue of $35.3 million, an increase of 59% compared to the third quarter of 2023, reflecting: • The s ...

ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference cal ...

ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced its plans to participate in two upcoming healthcare conferences in September. Morgan Stanley 22nd Annual Global Healthcare Conference - Fireside Chat: Wednesday, September 4, 2024, at 9:15 a.m. ET in New York City, NY Wells Fargo 2024 Healthcare Conference - Fireside Chat: Thur ...

Core Insights - RxSight, Inc. is a pioneering medical technology company focused on transforming cataract surgery with its innovative Light Adjustable Lens (LAL) system, which is the first FDA-approved premium intraocular lens that allows for postoperative adjustments [3][4] - The global cataract devices market is valued at $13 billion annually and is projected to grow to $20 billion by 2032, with RxSight positioned to capitalize on this growth due to its unique product offering [3][4] - The company reported a significant revenue increase of 68% in Q2 2024, driven by a 92% rise in Light Adjustable Lens sales, indicating strong market penetration and demand for its innovative solutions [5][6] Industry Overview - Cataracts affect approximately 50% of individuals by age 60, leading to a substantial market for cataract surgeries, with 31 million surgeries performed globally in 2023 [3] - The premium intraocular lens market, which represents about 21% of U.S. cataract surgeries, generated approximately $780 million in revenue in 2023 and is expected to grow at a CAGR of 9.5%, reaching $1.3 billion by 2028 [3] Company Performance - In Q2 2024, RxSight achieved total revenue of $34.9 million, with gross profit reaching $24.3 million, reflecting a gross profit margin of 69.5% [5][6] - Operating expenses increased to $32.6 million, primarily due to investments in expanding the Light Delivery Device installed base and supporting increased LAL sales volume [6] - The company has raised its full-year revenue guidance to $139 million to $140 million, indicating a growth of 56% to 57% compared to 2023 [6] Competitive Advantage - The LAL system offers unique postoperative adjustability, allowing for customized vision correction, which is not available with traditional fixed-power premium IOLs [4][9] - Clinical trials show that 70% of LAL patients achieved 20/20 vision without glasses, compared to only 40% with other premium IOLs, highlighting superior outcomes and lower incidences of side effects [4] Valuation and Market Sentiment - The stock is considered undervalued with a fair value estimated at $76, indicating potential upside for investors [7] - The mean sell-side analyst price target is $72, suggesting a 51% upside potential from current levels [8] - The company has received a Strong Buy rating from SA Quant, reflecting positive market sentiment following its impressive Q2 earnings report [8][9]

Core Viewpoint - RxSight, Inc. (RXST) shows potential for significant upside, with a mean price target of $64.75 indicating a 27.6% increase from the current trading price of $50.73 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $7.92, suggesting variability in analyst predictions [2] - The lowest price target is $54, indicating a 6.5% increase, while the highest target is $75, suggesting a potential surge of 47.8% [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement [7] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about RXST's earnings prospects, with a strong consensus in revising EPS estimates higher [9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 3.5%, with one estimate moving higher and no negative revisions [10] - RXST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11]

Company Overview - RxSight, Inc. is an ophthalmic medical device company focused on providing high-quality customized vision for patients after cataract surgery [1] - The RxSight® Light Adjustable Lens system is the first and only commercially available intraocular lens technology that can be adjusted post-surgery, allowing for tailored vision correction [1] Financial Reporting - The company will report its financial results for the second quarter of 2024 after market close on August 5, 2024 [3] - A conference call to discuss the financial results will take place at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day [3]

Core Viewpoint - RxSight, Inc. (RXST) has experienced a significant downtrend, with a 16.1% decline in stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold conditions, with a reading below 30 typically indicating that a stock is oversold [2]. - RXST's current RSI reading is 29.57, indicating that the heavy selling pressure may be exhausting itself, which could signal a potential price reversal [2][3]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts regarding an increase in earnings estimates for RXST, with a 1.3% rise in the consensus EPS estimate over the last 30 days [3]. - An upward trend in earnings estimate revisions is generally associated with price appreciation in the near term, further supporting the potential for RXST's stock to rebound [3]. - RXST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a favorable outlook for the stock [3].

Investor Relations Contact: Oliver Moravcevic VP, Investor Relations omoravcevic@rxsight.com RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+™, collectively the "LAL"), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Even though momentum is a popular stock cha ...